Dec 26 (Reuters) - CASI Pharmaceuticals Inc :
* CASI PHARMACEUTICALS INC: ANNOUNCES CLINICAL HOLD OF CID-103 FOR ANTIBODY MEDIATED REJECTION $(AMR)$ OF KIDNEY TRANSPLANT
* CASI PHARMACEUTICALS: FDA PLANS TO PROVIDE FORMAL WRITTEN RESPONSE BEFORE STATUTORY DEADLINE
* CASI PHARMACEUTICALS: CID-103 IND APPLICATION SUPPORTING PHASE 1-2 STUDY OF CID-103 IN ADULTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA REMAINS OPEN
* CASI PHARMACEUTICALS: ACCRUAL TO PHASE 1-2 STUDY OF CID-103 EXPECTED TO COMMENCE IN Q1 2025
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。